These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476 [TBL] [Abstract][Full Text] [Related]
3. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957 [TBL] [Abstract][Full Text] [Related]
4. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Stabile LP; Davis AL; Gubish CT; Hopkins TM; Luketich JD; Christie N; Finkelstein S; Siegfried JM Cancer Res; 2002 Apr; 62(7):2141-50. PubMed ID: 11929836 [TBL] [Abstract][Full Text] [Related]
5. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664 [TBL] [Abstract][Full Text] [Related]
7. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Dougherty SM; Mazhawidza W; Bohn AR; Robinson KA; Mattingly KA; Blankenship KA; Huff MO; McGregor WG; Klinge CM Endocr Relat Cancer; 2006 Mar; 13(1):113-34. PubMed ID: 16601283 [TBL] [Abstract][Full Text] [Related]
8. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034 [TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936 [TBL] [Abstract][Full Text] [Related]
11. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992 [TBL] [Abstract][Full Text] [Related]
12. Estrogenic and antiestrogenic activities of 2,4-diphenylfuran-based ligands of estrogen receptors alpha and beta. Zimmermann J; von Angerer E J Steroid Biochem Mol Biol; 2007 May; 104(3-5):259-68. PubMed ID: 17475477 [TBL] [Abstract][Full Text] [Related]
13. [Estrogen receptor expression in tumors different from breast cancer]. Bogush TA; Dudko EA; Beme AA; Bogush EA; Polotskiĭ BE; Tiuliandin SA; Davydov MI Antibiot Khimioter; 2009; 54(7-8):41-9. PubMed ID: 20201403 [TBL] [Abstract][Full Text] [Related]
14. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Shen H; Yuan Y; Sun J; Gao W; Shu YQ Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069 [TBL] [Abstract][Full Text] [Related]
15. Expression patterns and clinical significance of estrogen receptor in non-small cell lung cancer. Castellanos MR; Fanous E; Thaker R; Flory MJ; Seetharamu N; Dhar M; Starr A; Strange TJ Pathol Res Pract; 2023 Jan; 241():154298. PubMed ID: 36608623 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124 [TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological and prognostic significance of ERα and ERβ expression in lung carcinomas: a tissue microarray study]. Yang X; Xue LY; Liu Y; Guo L; Wen P; Lin DM Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):678-83. PubMed ID: 24332055 [TBL] [Abstract][Full Text] [Related]
18. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881 [TBL] [Abstract][Full Text] [Related]
19. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703 [TBL] [Abstract][Full Text] [Related]
20. Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: gender-dependent clinical outcome. Verma MK; Miki Y; Abe K; Nagasaki S; Niikawa H; Suzuki S; Kondo T; Sasano H Life Sci; 2012 Oct; 91(15-16):800-8. PubMed ID: 22982181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]